More than half a million doses of Sanofi’s meningococcal vaccine, Menactra, have arrived in Australia
The vaccine is indicated for people from two through to 55 years, to protect against meningococcal disease caused by four groups of Neisseria meningitides—A, C, Y and W-135.
Auspharm forum members discussed their problems accessing stock back in March.
Russell Jacobson, General Manager Sanofi Pasteur Australia said the boost in supply would ensure that the vaccine would be available to patients wanting to be vaccinated against the A, C, Y and W strains of meningococcal.
“In April this year Sanofi quickly responded to a number of important state based immunisation programs for adolescents,” he said.
“Since then our team has been working to ensure sufficient supply was maintained for other Australians who wanted to purchase the vaccine.
“This delivery of half a million Menactra doses will ensure it remains readily available to General Practice and pharmacy via the Australian private market.”
Meanwhile GSK’s meningococcal B vaccine Bexsero remains in shortage (as reported by AJP last year).
The Advocate, which serves the north-west and west coast of Tasmania, reported yesterday (May 31) that pharmacies in the area were left “depleted” by the worldwide shortage of the vaccine.
A GSK spokesperson told the paper that the company planned to bring an additional 200,000 Bexsero doses to Australia early in June.